Medicaid programs willing to boot out drug pricing middlemen
Axios
— By Bob Herman, October 8, 2019
Michigan’s Medicaid program is proposing to fire the pharmacy benefit managers that handle its prescription drug claims and negotiate prices. The state would manage drug coverage itself, starting Dec. 1.
The big picture: More state Medicaid agencies have determined that outsourcing all negotiations and operations of prescription drugs to PBMs has not produced the dramatic savings they were promised.
Details: Michigan officials said in a bulletin the state could extract bigger rebates from pharmaceutical companies and cut administrative costs if the state handled all Medicaid medication benefits, instead of the current private contractors.
- Michigan would use Magellan as its sole drug claims processor.
- A spokesperson for the Michigan Department of Health and Human Services said the proposal would save $40 million, and officials “will be reviewing the feedback carefully to determine next steps.”
- CVS Health, OptumRx, MedImpact and a handful of other PBMs stand to lose business.
Between the lines: State governments, along with pharmacists, continue to lead the crusades against PBMs.
- A recently signed California regulation will shift all Medicaid drug benefits away from PBMs by 2021, and West Virginia’s Medicaid department fired its PBMs in 2017.
Recent Posts
-
Drug Pricing Law Worsens Access Crisis for Nursing Homes, Long-Term Care Pharmacies Amid Huge Reimbursement Gap
With reimbursement for brand name drugs sharply decreasing under the Inflation Reduction Act, long-term care pharmacies are having to make difficult decisions that will have a lasting impact on nursing home residents.
-
CMS must act now to safeguard seniors’ access to long-term care pharmacies
By Jessica Androff & Xhulia Rapo | McKnights Long-Term Care News The Medicare program relies on long-term care pharmacies (LTCPs) to protect some of the most medically complex patients that reside in long-term care settings, yet current payment policies are unfortunately not optimized to protect access to care. As the Centers for Medicare & Medicaid […]
-
NCPA Advocates for Medicare Drug Price Negotiation Program Overhaul Due to Pharmacy Cash Flow
With its initial rollout beginning in 2026, the Medicare Drug Price Negotiation Program has caused significant strain on the cash flow of independent pharmacies.
The National Community Pharmacists Association (NCPA) is sounding the alarm over the federal government’s implementation of the Medicare Drug Price Negotiation Program (MDPNP) after a recent survey of its members revealed significant financial distress, according to a news release.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.